Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 21 December 1984:
Vol. 226. no. 4681, pp. 1454 - 1456
DOI: 10.1126/science.6150550
Prev | Table of Contents | Next

Articles

Science, Vol 226, Issue 4681, 1454-1456
Copyright © 1984 by American Association for the Advancement of Science

articles

Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines

E Kornecki, YH Ehrlich, and RH Lenox

Platelet-activating factor (PAF), a naturally occurring phospholipid, is a potent activator of various biological processes, including platelet aggregation. The mechanisms by which PAF acts are largely unknown, partly because of the lack of specific inhibitors for PAF-elicited responses. It was found that in washed human platelets the psychotropic triazolobenzodiazepine drugs alprazolam and triazolam potently inhibited PAF-induced changes in shape, aggregation, and secretion. The effects were specific for PAF activation, since the responses of human platelets to adenosine diphosphate, thrombin, epinephrine, collagen, arachidonate, and the calcium ionophore A23187 were not inhibited by the triazolobenzodiazepines. These psychotropic drugs should be useful in investigating the possibility that PAF or PAF-like phospholipids play a role in neuronal function and in elucidating biochemical mechanisms activated specifically by PAF in a variety of cells.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Suppression of Monocyte Chemoattractant Protein 1, But Not IL-8, by Alprazolam: Effect of Alprazolam on c-Rel/p65 and c-Rel/p50 Binding to the Monocyte Chemoattractant Protein 1 Promoter Region.
T. Oda, A. Ueda, N. Shimizu, H. Handa, and T. Kasahara (2002)
J. Immunol. 169, 3329-3335
   Abstract »    Full Text »    PDF »
Inverse Agonist Activity of Selected Ligands of Platelet-Activating Factor Receptor.
D. J. Dupre, C. Le Gouill, M. Rola-Pleszczynski, and J. Stankova (2001)
J. Pharmacol. Exp. Ther. 299, 358-365
   Abstract »    Full Text »    PDF »
Interactions of Benzodiazepine Derivatives with Annexins.
A. Hofmann, A. Escherich, A. Lewit-Bentley, J. Benz, C. Raguenes-Nicol, F. Russo-Marie, V. Gerke, L. Moroder, and R. Huber (1998)
J. Biol. Chem. 273, 2885-2894
   Abstract »    Full Text »    PDF »
Platelet-Activating Factor Receptor Stimulation Disrupts Neuronal Migration In Vitro.
G. J. Bix and G. D. Clark (1998)
J. Neurosci. 18, 307-318
   Abstract »    Full Text »    PDF »
Neuroregulatory and neuropathological actions of the ether-phospholipid platelet-activating factor.
E Kornecki and Y. Ehrlich (1988)
Science 240, 1792-1794
   Abstract »    PDF »
Overview of the Cross-National Collaborative Panic Study: I. Efficacy in Short-term Treatment.
G. L. Klerman (1988)
Arch Gen Psychiatry 45, 407-412
   Abstract »    PDF »
Role of platelet-activating factor-acether in mediating guinea pig anaphylaxis.
H Darius, D. Lefer, J. Smith, and A. Lefer (1986)
Science 232, 58-60
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)